- Home
- ARBK vs CELU Comparison
ARBK vs CELU Comparison
Compare ARBK & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBK
- CELU
- Stock Information
- Founded
- ARBK 2017
- CELU 2016
- Country
- ARBK United Kingdom
- CELU United States
- Employees
- ARBK N/A
- CELU N/A
- Industry
- ARBK Finance: Consumer Services
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- ARBK Finance
- CELU Health Care
- Exchange
- ARBK Nasdaq
- CELU Nasdaq
- Market Cap
- ARBK 42.6M
- CELU 50.4M
- IPO Year
- ARBK 2021
- CELU N/A
- Fundamental
- Price
- ARBK $0.59
- CELU $2.30
- Analyst Decision
- ARBK Hold
- CELU
- Analyst Count
- ARBK 2
- CELU 0
- Target Price
- ARBK $1.45
- CELU N/A
- AVG Volume (30 Days)
- ARBK 574.5K
- CELU 89.6K
- Earning Date
- ARBK 11-20-2024
- CELU 12-06-2024
- Dividend Yield
- ARBK N/A
- CELU N/A
- EPS Growth
- ARBK N/A
- CELU N/A
- EPS
- ARBK N/A
- CELU N/A
- Revenue
- ARBK $52,868,000.00
- CELU $48,200,000.00
- Revenue This Year
- ARBK N/A
- CELU N/A
- Revenue Next Year
- ARBK $175.58
- CELU $233.89
- P/E Ratio
- ARBK N/A
- CELU N/A
- Revenue Growth
- ARBK 18.91
- CELU 225.94
- 52 Week Low
- ARBK $0.52
- CELU $1.30
- 52 Week High
- ARBK $2.92
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- ARBK 39.45
- CELU 52.94
- Support Level
- ARBK $0.55
- CELU $2.04
- Resistance Level
- ARBK $0.64
- CELU $2.39
- Average True Range (ATR)
- ARBK 0.06
- CELU 0.17
- MACD
- ARBK 0.01
- CELU 0.02
- Stochastic Oscillator
- ARBK 31.88
- CELU 70.76
About ARBK Argo Blockchain plc
Argo Blockchain PLC is a data center business that provides a powerful and efficient platform for cryptocurrency mining operations. The company has operations in strategic locations in North America.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.